Experts weigh over-the-counter glucose monitors for children 2 and older

For the first time in the United States, children as young as 2 can get a continuous glucose monitor without a doctor’s prescription. That change has prompted a question that experts are now weighing: Is broader access to these devices a good thing for young children?

The Food and Drug Administration says yes. Last month, when it cleared Dexcom’s Stelo for marketing, the agency said the devices can give pediatric patients and their caregivers real-time glucose data. According to the FDA, that information may help families build greater awareness of glucose levels, see how readings change in response to meals and exercise, and make informed adjustments that could support healthier long-term outcomes and quality of life.

The new access marks a notable shift in how continuous glucose monitors, often called CGMs, may be used in the U.S. With over-the-counter approval, they are no longer limited to people who have a doctor’s prescription. The change means families may now be able to obtain the devices more easily, including for young children.

At the same time, not everyone sees the expansion as straightforward. Some clinicians welcome CGMs as a new tool, while others worry about whether wider use could contribute to disordered eating. The source material does not provide details on which clinicians hold those views, how common the concerns are, or what specific patterns of use might be most problematic.

CGMs are designed to provide ongoing glucose readings rather than one-time measurements. In the context described by the FDA, the promise of that data is not a diagnosis or treatment on its own, but a clearer picture of how glucose changes over time. For caregivers, that could mean more immediate feedback about daily routines and how a child responds to food or activity.

Still, the question raised by the headline remains unresolved in the available source material: whether the benefits of over-the-counter glucose monitoring outweigh the risks for a 2-year-old. The published excerpt does not report any clinical trial results, expert consensus, age-specific recommendations, or data showing how children or families have actually used the devices since the FDA decision.

The story also does not say whether the FDA set any special conditions for use in children, what types of families are most likely to seek the monitors, or whether pediatricians expect the devices to become common in routine care. Those details were not reported in the source provided.

What is clear from the FDA’s statement is that the agency believes real-time glucose information may help children and caregivers make more informed choices. What remains open is how that potential will play out in practice, and whether clinicians’ concerns about possible harms will prove justified.

For now, the approval has widened access to a technology that was once more closely tied to prescription use. As a result, families and clinicians are left to consider both the appeal of more data and the possibility that more monitoring is not always better, especially for very young children.